Trials / Withdrawn
WithdrawnNCT04473924
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Infections are common and associated with poor outcomes as well as high financial costs after kidney transplantation. Identifying and implementing strategies to reduce infections after kidney transplantation is important for improving patient outcomes. This study seeks to determine the feasibility of body surface area-based dosing of mycophenolate compared to standard dosing of mycophenolate in a pilot randomized controlled trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mycophenolate Mofetil | Body surface area-based dosing of mycophenolate |
| DRUG | Mycophenolate Mofetil | Standard (fixed) dosing of mycophenolate |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-01-01
- Completion
- 2023-05-01
- First posted
- 2020-07-16
- Last updated
- 2022-05-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04473924. Inclusion in this directory is not an endorsement.